TY - JOUR
T1 - Post-marketing studies of drug efficacy
T2 - How?
AU - Strom, Brian L.
AU - Miettinen, Olli S.
AU - Melmon, Kenneth L.
N1 - Funding Information:
From the Clinical Epidemiology Unit, Section of General Medicine, Departments of Medicine and Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, the Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, Massachusetts, and the Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Stanford University Medical School, Stanford, California. This work was supported by a grant from the Joint Commission on Prescription Drug Use, by National Institutes of Health Training Grant GM-07546, and by grants from the Charles A. Dana Foundation, the Rockefeller Foundation, and the Andrew W. Mellon Foundation. Requests for reprints should be addressed to Dr. Brian L. Strom, 225L NEB/SP, University of Pennsylvania School of Medkzine, Philadelphia, Pennsylvania 19104. Manuscript accepted April 4, 1964.
PY - 1984/10
Y1 - 1984/10
N2 - This report reviews the 100 most recently approved drugs in order to quantify the frequency with which post-marketing studies of drug efficacy can be performed experimentally and non-experimentally. These drugs represent 131 potential drug uses. Of them, the absolute efficacy of 89 (68 percent) could be evaluated from clinical observations. Of the remaining 42, six (14 percent) could be studied experimentally or non-experimentally, six (14 percent) only experimentally, one (2 percent) only non-experimentally, and 29 (69 percent) by neither technique. Answers to all questions of relative efficacy required formal research. Of these, 94 (72 percent) could be studied using either experimental or non-experimental techniques. The remaining 37 (28 percent) could be studied experimentally only. Thus, clinical observations and non-experimental research can contribute a large proportion of the information about drug efficacy still needed after marketing.
AB - This report reviews the 100 most recently approved drugs in order to quantify the frequency with which post-marketing studies of drug efficacy can be performed experimentally and non-experimentally. These drugs represent 131 potential drug uses. Of them, the absolute efficacy of 89 (68 percent) could be evaluated from clinical observations. Of the remaining 42, six (14 percent) could be studied experimentally or non-experimentally, six (14 percent) only experimentally, one (2 percent) only non-experimentally, and 29 (69 percent) by neither technique. Answers to all questions of relative efficacy required formal research. Of these, 94 (72 percent) could be studied using either experimental or non-experimental techniques. The remaining 37 (28 percent) could be studied experimentally only. Thus, clinical observations and non-experimental research can contribute a large proportion of the information about drug efficacy still needed after marketing.
UR - http://www.scopus.com/inward/record.url?scp=0021127236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021127236&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(84)90369-3
DO - 10.1016/0002-9343(84)90369-3
M3 - Article
C2 - 6486146
AN - SCOPUS:0021127236
SN - 0002-9343
VL - 77
SP - 703
EP - 708
JO - The American Journal of Medicine
JF - The American Journal of Medicine
IS - 4
ER -